Background In the placebo-controlled phase III SATURN study, maintenance erlotinib after
first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) …

Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …

Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …

Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …

Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …

The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …

Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …

Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …

Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome in non-small-cell lung cancer …